Octapharma has published the final results from the NuProtect study on Nuwiq. The medicine Nuwiq has been developed to treat patients with the inherited condition hemophilia A. This hereditary bleeding disorder is caused by a deficiency of a particular protein in the blood. Patients with this condition can suffer bleeding episodes and the risk of permanent joint damage.
In the study, Nuwiq was given to previously untreated patients with severe hemophilia A, as was reported in a press release. It assessed the immunogenicity, efficacy and safety of Nuwiq.
The results show that there was a low risk of inhibitor development in previously untreated patients starting treatment with Nuwiq, said Dr Ri Liesner, coordinating investigator of the NuProtect study and clinician at Great Ormond Street Hospital for Children in London. The development of inhibitors to replacement factor VIII is a concern for doctors and patients, because it limits treatment options.
Nuwiq was developed in a human cell line with the aim of minimizing inhibitor risk in previously untreated patients, explained Larisa Belyanskaya, Head of IBU Hematology at Octapharma. “We are pleased to be able to share these positive data, which reflect this aim and which we hope will contribute to addressing this key treatment challenge,” Belyanskaya added.
Octapharma is headquartered in Lachen in the canton of Schwyz and claims to be one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines.
Watch the video and learn why bluebird bio set up shop in Greater Zurich: